Skip to content


Critical Care

Open Access

Catecholamine index is a simple and useful marker for bacteremic patients treated by polymyxin B hemoperfusion therapy

  • Y Isa1,
  • N Harayama1,
  • H Arai1,
  • T Shinjou1,
  • K Nagata1,
  • M Ueki1,
  • S Nihei1,
  • K Aibara1 and
  • M Kamochi1
Critical Care201115(Suppl 1):P119

Published: 1 March 2011


Mean Arterial PressureLactate ConcentrationSurvivor GroupPolymyxinSepsis Patient


Polymyxin B hemoperfusion therapy has been used for the treatment of sepsis to reduce blood endotoxin levels and a variety of inflammatory mediators. There are many reports that polymyxin B hemoperfusion therapy potentially improves circulatory dynamics and reduces mortality [1, 2]. However, it is still controversial what is an important predictive factor to define the mortality. We analyzed a relationship between circulatory dynamics and mortality in our cases of polymyxin B hemoperfusion therapy.


From January 2007 to June 2010, 69 patients who received polymyxin B hemoperfusion therapy were retrospectively reviewed. Two child cases, six cases of 24-hour death and the seven cases in whom bacteremia was not detected by blood culture test were excluded. In total, for 54 patients information including characteristics, etiological microorganisms, circulatory dynamics (catecholamine index (CAI) and mean arterial pressure (MAP)), lactate concentration and mortality was investigated. We divided the patients into survivor and nonsurvivor groups and compared these two groups. The statistical analyses were performed by unpaired t test.


Thirty-four patients (63.0%) survived and 20 patients (37.0%) died. Before polymyxin B hemoperfusion therapy, there were no significant differences in CAI, MAP and lactate concentration (CAI: 23.6 ± 26.5 (mean ± SD) vs. 34.0 ± 25.3, MAP: 69.7 ± 16.7 vs. 62.0 ± 16.7 mmHg, lactate: 4.0 ± 2.6 vs. 4.4 ± 3.6 mmol/l). But 2 hours after polymyxin B hemoperfusion therapy, only the CAI of the survivor group was significantly lower than in the nonsurvivor group (14.2 ± 14.1 vs. 30.4 ± 25.5; P < 0.01). However, MAP and lactate concentration did not show significant differences between the two groups (MAP: 80.1 ± 13.0 vs. 78.0 ± 15.4, lactate: 2.5 ± 1.3 vs. 3.6 ± 3.2). At 24 hours after polymyxin B hemoperfusion therapy, the CAI difference between the two groups was became more remarkable (6.09 ± 9.02 vs. 27.18 ± 29.31; P < 0.01).


The CAI after polymyxin B hemoperfusion therapy was highly related to mortality, although the CAI before that therapy was not. Polymyxin B hemoperfusion therapy improve the circulatory dynamics of most sepsis patients, but the efficacy of that therapy to decreasing catecholamine is one of the important prognosis predictors for bacteremic patients.

Authors’ Affiliations

University of Occupational and Environmental Health Japan, Kitakyushu City, Fukuoka, Japan


  1. Cruz DN, et al.: JAMA. 2009, 301: 2445-2451.View ArticlePubMedGoogle Scholar
  2. Cruz DN, et al.: Crit Care. 2007, 11: R47.PubMed CentralView ArticlePubMedGoogle Scholar


© Isa et al. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.